Conclusion
Since the approval of dornase alfa in 1993, several drugs have been developed and approved by regulatory agencies specifically for people with CF. This process has (so far) culminated in 2020, with approval of highly-effective modulators for approximately 90% of people with CF ages 12 years and older. These transformative therapies will surely reduce morbidity and extend longevity, yet not all people with CF will have access to these drugs. The therapeutic development pipeline contains candidate drugs that address many different aspects of disease, although many face particular challenges to being approved. However, the challenges of drug development must be met until that time when a one-time cure is available to all people with CF.